In this manuscript we provide evidence that the complementation of the baseline neurological medication of PKAN patients with pantothenate, pantethine (aiming to increase PANK2 and mtACP levels) and omega 3 and vitamin E (targeting oxidative stress and lipid peroxidation) could help in improving or delaying the progression of motor dysfunction. Here, PANK2 is linked to pantothenate kinase-associated neurodegeneration.